AI Investing Insights - Official Homepage

All Hong Kong stocks quotes are at least 15 minutes delayed.

02105

LAEKNA-B

HKD

13.470

-0.630

(-4.47%)

High

14.100

Open

14.100

VWAP

13.42

Vol

3.19M

Mkt Cap

7.48B

Low

13.080

Amount

42.79M

EV/EBITDA(TTM)

Total Shares

446.47M

719.18M

EV/OCF(TTM)

P/S(TTM)

Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.

News

8.5

2025-09-10aastocks

LAEKNA-B Shares Plunge Over 16% Following 9.5% Discounted Share Placement to Secure HKD578M Net Funds

8.5

2025-09-10aastocks

LAEKNA-B Offers Shares at a 9.5% Discount to Generate $578 Million in Net Proceeds

Money Flow

Over the past 66 trading days, overall net money flow is -9.01M, with retail investors contributing -2.36M and major investors adding -7.44M.

Net Buy $ Volume

Net Sell $ Volume

DBS Research

Buy

downgrade

2025-09-30

Reason

DBS Research lowered its target price for LAEKNA-B from HKD26.45 to HKD24.16 due to the dilution of shares following a capital raising. However, they maintained a Buy rating primarily because the financing has significantly increased the likelihood of Eli Lilly and Company licensing LAE102, a drug aimed at preventing muscle loss. Additionally, the capital raising has improved LAEKNA-B's cash reserves, allowing it to sustain operations for approximately three years, compared to two years previously.

DBS Research

Buy

Price Target

2025-09-30

downgrade

Valuation Metrics

Forward PE

N/A

5Y Average PE

-8.02

Current PE

-18.15

Overvalued PE

2.34

Undervalued PE

-18.39

Forward EV/EBITDA

N/A

5Y Average EV/EBITDA

-6.33

Current EV/EBITDA

-15.23

Overvalued EV/EBITDA

1.90

Undervalued EV/EBITDA

-14.55

Forward PS

N/A

5Y Average PS

190.09

Current PS

0.00

Overvalued PS

474.42

Undervalued PS

-94.24

Financials

Al Analysis

Annual

Quarterly

Trading Trends

Daily

Monthly

No data

Short Selling

People Also Watch